Graybug Vision Completes Treatment Phase of ALTISSIMO Trial in Wet AMD with 12-Month Topline Data Expected in Second Quarter 2021
07. Januar 2021 07:30 ET
|
Graybug Vision, Inc.
REDWOOD CITY, Calif., Jan. 07, 2021 (GLOBE NEWSWIRE) -- Graybug Vision, Inc. (Nasdaq: GRAY), a clinical-stage biopharmaceutical company focused on developing transformative medicines to treat...
CalciMedica Announces IDMC Recommendation to Continue with Trial Evaluating Auxora™ in Patients with Severe COVID-19 Pneumonia
17. Dezember 2020 08:00 ET
|
CalciMedica
Blinded placebo-controlled trial is expected to enroll more than 100 patients at U.S. clinical sites by end of DecemberThe Company expects to complete enrollment of the trial by the end of Q1 2021 LA...
Graybug Vision to Participate in the 32nd Annual Piper Sandler Healthcare Conference
16. November 2020 16:05 ET
|
Graybug Vision, Inc.
REDWOOD CITY, Calif., Nov. 16, 2020 (GLOBE NEWSWIRE) -- Graybug Vision, Inc. (Nasdaq: GRAY), a clinical-stage biopharmaceutical company focused on developing transformative medicines for the...
CalciMedica Announces Publication of Preclinical Data Demonstrating the Pathological Role of Microglial CRAC Channels in Ischemic Stroke
13. November 2020 08:00 ET
|
CalciMedica
First report of pathological role for microglial calcium activity in cortical spreading depolarization (CSD), a complication of strokeCRAC channel inhibitors represent an important future potential...
Graybug Vision Announces Financial Results for the Three and Nine Months Ended September 30, 2020 and Recent Corporate Developments
12. November 2020 16:05 ET
|
Graybug Vision, Inc.
REDWOOD CITY, Calif., Nov. 12, 2020 (GLOBE NEWSWIRE) -- Graybug Vision, Inc. (Nasdaq: GRAY), a clinical-stage biopharmaceutical company focused on developing transformative medicines for the...
CalciMedica Appoints Daniel Geffken as Interim Chief Financial Officer
05. November 2020 08:00 ET
|
CalciMedica
Mr. Geffken brings more than three decades of financial experience to CalciMedica; involved in 12 IPO filings since 2013 LA JOLLA, Calif., Nov. 05, 2020 (GLOBE NEWSWIRE) -- CalciMedica Inc....
Graybug Appoints Three New Members to its Board of Directors
25. September 2020 08:00 ET
|
Graybug Vision, Inc.
REDWOOD CITY, Calif., Sept. 25, 2020 (GLOBE NEWSWIRE) -- Graybug Vision, Inc. (Nasdaq: GRAY), a clinical-stage biopharmaceutical company focused on developing transformative medicines to treat...
Graybug Vision Announces Pricing of Upsized Initial Public Offering
24. September 2020 20:12 ET
|
Graybug Vision, Inc.
REDWOOD CITY, Calif., Sept. 24, 2020 (GLOBE NEWSWIRE) -- Graybug Vision, Inc. (Nasdaq: GRAY), a clinical-stage biopharmaceutical company focused on developing transformative medicines to treat...
Graybug Vision Appoints Robert Breuil as Chief Financial Officer
04. September 2020 07:00 ET
|
Graybug Vision, Inc.
REDWOOD CITY, Calif., Sept. 04, 2020 (GLOBE NEWSWIRE) -- Graybug Vision, Inc. (“Graybug”), a clinical stage biopharmaceutical company focused on developing transformative medicines to treat chronic...
CalciMedica Announces Peer-Reviewed Publication of Positive COVID-19 Data and Initiation of Blinded, Placebo-Controlled Trial of Auxora™ in Patients with Severe COVID-19 Pneumonia
18. August 2020 08:00 ET
|
CalciMedica
Study published in Critical Care journal shows patients with severe COVID-19 pneumonia treated with Auxora and standard of care had substantially improved outcomes compared to patients on standard of...